Get Live Data

Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share Regulatory News
  5. Total Voting Rights

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

1 Oct 2020 16:30

RNS Number : 8675A
GlaxoSmithKline PLC
01 October 2020
 

 

GlaxoSmithKline plc

 

Total Voting Rights and Capital

 

 

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following:

 

The Company's issued share capital as at 30 September 2020 consisted of 5,385,081,188 shares of 25 pence each ('Ordinary Shares'), of which 367,705,950 Ordinary Shares were held in Treasury.

 

Therefore, the total number of voting rights in the Company is 5,017,375,238. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

 

 

V A Whyte

Company Secretary

 

1 October 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRUPGRGUUPUGAG
121314151617181920
Date   Source Headline
4th Sep 20195:37 pmRNSDirector/PDMR Shareholding
4th Sep 201912:36 pmRNSDirector/PDMR Shareholding
4th Sep 20199:33 amRNSDirector/PDMR Shareholding
2nd Sep 201911:29 amRNSTotal Voting Rights
23rd Aug 20197:00 amRNSGSK - positive results from pivotal DREAMM-2 study
22nd Aug 20197:00 amRNSViiV results positive for every 2 month injection
21st Aug 20198:00 amRNSGSK submits regulatory file in Japan: Daprodustat
12th Aug 20193:45 pmRNSDirector/PDMR Shareholding
1st Aug 20193:30 pmRNSEU approval for Nucala self-administration
1st Aug 20192:10 pmRNSTotal Voting Rights
1st Aug 20197:00 amRNSGSK completes transaction with Pfizer for New JV
30th Jul 20193:35 pmRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSViiV submits cabotegravir to EMA for HIV injection
24th Jul 20196:01 pmRNSDirector/PDMR Shareholding
24th Jul 20194:01 pmRNSViiV 2DR TANGO switch study positive at 48 weeks
24th Jul 20194:00 pmRNSViiV GEMINI studies show high efficacy at 96 weeks
24th Jul 201912:07 pmRNSSecond Price Monitoring Extn
24th Jul 201912:02 pmRNSPrice Monitoring Extension
24th Jul 201912:00 pmRNS2nd Quarter Results
24th Jul 201910:00 amRNSNon-Executive Chairman
22nd Jul 20195:00 pmRNSViiV presents 96-week data from phase III study
15th Jul 20196:19 pmRNSDirector/PDMR Shareholding
15th Jul 20196:18 pmRNSDirector/PDMR Shareholding
15th Jul 20196:16 pmRNSDirector/PDMR Shareholding
15th Jul 201911:42 amRNSDirector/PDMR Shareholding
15th Jul 20197:00 amRNSpositive results in Phase 3 PRIMA study of ZEJULA
12th Jul 20194:35 pmRNSDirector/PDMR Shareholding
12th Jul 20193:55 pmRNSDirector/PDMR Shareholding
10th Jul 20193:48 pmRNSDirector/PDMR Shareholding
10th Jul 20197:00 amRNSViiV switch study shows 2DR as effective as 3DR
1st Jul 201912:08 pmRNSTotal Voting Rights
12th Jun 20195:10 pmRNSDirector/PDMR Shareholding
7th Jun 20197:00 amRNSFDA approval for Nucala self-administration
4th Jun 20198:00 amRNSCHMP positive on GSK's Nucala self-administration
3rd Jun 20192:31 pmRNSTotal Voting Rights
24th May 201910:54 amRNSDirector/PDMR Shareholding
20th May 20191:44 pmRNSDirector/PDMR Shareholding
13th May 20195:44 pmRNSBlock listing Interim Review
13th May 20194:19 pmRNSDirector/PDMR Shareholding
8th May 20196:23 pmRNSResult of AGM & GM
2nd May 20195:07 pmRNSTrelegy Ellipta asthma study met primary endpoint
1st May 20193:11 pmRNSDirector/PDMR Shareholding
1st May 20192:32 pmRNSTotal Voting Rights
1st May 201912:00 pmRNS1st Quarter Results
29th Apr 201912:00 pmRNSViiV submits NDA for HIV monthly 2 drug injectable
26th Apr 20194:16 pmRNSViiV receives CHMP Positive Opinion for Dovato
16th Apr 20195:36 pmRNSDirector/PDMR Shareholding
16th Apr 20195:35 pmRNSDirector/PDMR Shareholding
16th Apr 20195:23 pmRNSDirector/PDMR Shareholding
16th Apr 20195:14 pmRNSDirector/PDMR Shareholding
121314151617181920

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.